Yalcin, A. D. Et Al. 2016. Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY , vol.38, no.3 , 253-256.

Yalcin, A. D., Celik, B., & YALÇIN, A. N., (2016). Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY , vol.38, no.3, 253-256.

Yalcin, Arzu, Betul Celik, And ATA NEVZAT YALÇIN. "Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels," IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY , vol.38, no.3, 253-256, 2016

Yalcin, Arzu D. Et Al. "Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels." IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY , vol.38, no.3, pp.253-256, 2016

Yalcin, A. D. Celik, B. And YALÇIN, A. N. (2016) . "Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels." IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY , vol.38, no.3, pp.253-256.

@article{article, author={Arzu Didem Yalcin Et Al. }, title={Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels}, journal={IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY}, year=2016, pages={253-256} }